SSG
NRXP icon

Summit Securities Group’s NRX Pharmaceuticals NRXP Stock Holding History

Summit Securities Group’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.42K Buy
+1,135
New +$2.29K ﹤0.01% 923

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Summit Securities Group's NRXP Position: Q1 2026 in Review

Summit Securities Group opened a new position in NRX Pharmaceuticals (NRXP) in Q1 2026: 1,135 shares worth $2.42K. The stake represents ﹤0.01% of the portfolio and ranks #923 among its holdings.

33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

  • Summit Securities Group held 1,135 shares of NRX Pharmaceuticals worth $2.42K as of Q1 2026.
  • NRX Pharmaceuticals was a new Summit Securities Group position in Q1 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Summit Securities Group's portfolio in Q1 2026, its #923 holding.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.